UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | D | E | F | G | H | J | K | L | M | N | O | P | R | S | T | V | W | Z
Number of items: 90.


Arcaro, A; Khanzada, UK; Vanhaesebroeck, B; Tetley, TD; Waterfield, MD; Seckl, MJ; (2002) Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation. EMBO JOURNAL , 21 (19) pp. 5097-5108. 10.1093/emboj/cdf512.

Arkenau, HT; Stichtenoth, DO; Frölich, JC; Manns, MP; Böker, KH; (2002) Elevated nitric oxide levels in patients with chronic liver disease and cirrhosis correlate with disease stage and parameters of hyperdynamic circulation. Z Gastroenterol , 40 (11) pp. 907-913. 10.1055/s-2002-35413.

Arkenau, HT; Widjaja, A; (2002) [A rare case of cholestasis and macrohematuria in a 52-year-old patient]. Med Klin (Munich) , 97 (8) pp. 480-483.

Atalay, G; Biganzoli, L; Renard, F; Paridaens, R; Batter, V; Coleman, R; Piccart, M; (2002) Clinical outcome of breast cancer patients with liver metastases in the anthracycline-taxane era. Breast Cancer Research and Treatment , 76 138 - ?.


Baraldi, PG; Romagnoli, R; Guadix, AE; de las Infantas, MJP; Gallo, MA; Espinosa, A; Martinez, A; (2002) Design, synthesis, and biological activity of hybrid compounds between uramustine and DNA minor groove binder distamycin A. J MED CHEM , 45 (17) 3630 - 3638. 10.1021/jm011113b.

Baraldi, PG; Romagnoli, R; Pavani, MG; Nunez, MD; Bingham, JP; Hartley, JA; (2002) Benzoyl and cinnamoyl nitrogen mustard derivatives of benzoheterocyclic analogues of the tallimustine: Synthesis and antitumour activity. BIOORGAN MED CHEM , 10 (5) 1611 - 1618.

Baselga, J; Rischin, D; Ranson, M; Calvert, H; Raymond, E; Kieback, DG; Kaye, SB; (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J CLIN ONCOL , 20 (21) 4292 - 4302. 10.1200/JCO.2002.03.100.

Batey, MA; Wright, JG; Azzabi, A; Newell, DR; Lind, MJ; Calvert, AH; Boddy, AV; (2002) Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). EUR J CANCER , 38 (8) 1081 - 1089.

Bentzen, SM; Saunders, MI; Dische, S; (2002) From CHART to CHARTWEL in non-small cell lung cancer: Clinical radiobiological modelling of the expected change in outcome. Clinical Oncology , 14 (5) pp. 372-381.

Biganzoli, L; Cufer, T; Bruning, P; Coleman, R; Duchateau, L; Calvert, AH; Gamucci, T; (2002) Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J CLIN ONCOL , 20 (14) 3114 - 3121. 10.1200/JCO.2002.11.005.

Boddy, AV; Todd, R; Verrill, M; Sludden, J; Fishwick, K; Robson, L; Cassidy, J; (2002) Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study. European Journal of Cancer , 38 98 - ?.

Bomanji, JB; Syed, R; Brock, C; Jankowska, P; Dogan, A; Costa, DC; Ell, PJ; (2002) Challenging cases and diagnostic dilemmas: case 2. Pitfalls of positron emission tomography for assessing residual mediastinal mass after chemotherapy for Hodgkin's disease. J Clin Oncol , 20 (15) pp. 3347-3349. 10.1200/JCO.2002.20.15.3347.

Brett, BT; Smith, SC; Bouvier, CV; Michaeli, D; Hochhauser, D; Davidson, BR; Kurzawinski, TR; (2002) Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J CLIN ONCOL , 20 (20) 4225 - 4231. 10.1200/JCO.2002.11.151.

Brock, CS; Lee, SM; (2002) Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer. EUROPEAN RESPIRATORY JOURNAL , 19 (3) pp. 557-570. 10.1183/09031936.02.00293002.

Brooks, LA; Sullivan, A; O'Nions, J; Bell, A; Dunne, B; Tidy, JA; Evans, DJ; (2002) E7 proteins from oncogenic human papillomavirus types transactivate p73: role in cervical intraepithelial neoplasia. BRITISH JOURNAL OF CANCER , 86 (2) pp. 263-268. 10.1038/sj/bjc/6600033.

Bunn, PA; Calvert, H; (2002) Pemetrexed, a novel multitargeted antifolate: Current development and future directions - Introduction. SEMIN ONCOL , 29 (2) 1 - 2. 10.1053/sonc.2002.30757.


Calvert, AH; Egorin, MJ; (2002) Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. EUR J CANCER , 38 (1) 11 - 16.

Calvert, H; (2002) Folate status and the safety profile of antifolates. SEMINARS IN ONCOLOGY , 29 (2) 3 - 7. 10.1053/sonc.2002.30761.

Calvert, H; Bunn, PA; (2002) Future directions in the development of pemetrexed. SEMINARS IN ONCOLOGY , 29 (2) 54 - 61. 10.1053/sonc.2002.30761.

Calvert, H; Jodrell, DI; Cassidy, J; Harris, AL; (2002) Efficacy, safety, and cost of new anticancer drugs - Pessimistic conclusion was not justified. BRIT MED J , 325 (7375) 1302 - 1303.

Casey, JL; Napier, MP; King, DJ; Pedley, RB; Chaplin, LC; Weir, N; Skelton, L; (2002) Tumour targeting of humanised cross-linked divalent-fab ' antibody fragments: a clinical phase I/II study. BRIT J CANCER , 86 (9) 1401 - 1410. 10.1038/sj/bjc/6600198.

Cooke, SP; Pedley, RB; Boden, R; Begent, RH; Chester, KA; (2002) In vivo tumor delivery of a recombinant single chain Fv::tumor necrosis factor-alpha fusion [correction of factor: a fusion] protein. Bioconjug Chem , 13 (1) pp. 7-15.

Craddock, C; Hochhauser, D; (2002) Realising the potential of targeted therapies in oncology. LANCET , 360 (9331) 424 - 425.


De Silva, IU; McHugh, PJ; Clingen, PH; Hartley, JA; (2002) Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. NUCLEIC ACIDS RES , 30 (17) 3848 - 3856. Gold open access


El-Emir, E; Petrie, ; I, A; Boxer, ; G, M; Boden, ; R, ; (2002) Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. In: (Proceedings) Proceedings BACR, Br J Cancer. (pp. 257-).

El-Emir, E; Petrie, IA; Boxer, GM; Boden, R; Dearling, JLJ; Raleigh, JA; Mantavani, A; (2002) Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. BRIT J CANCER , 86 S112 - S112.


Flynn, AA; Green, AJ; Pedley, RB; Boxer, GM; Dearling, J; Watson, R; Boden, R; (2002) A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection. Cancer , 94 (4 Suppl) pp. 1249-1257.

Flynn, AA; Green, AJ; Pedley, RB; Boxer, GM; Dearling, J; Watson, R; Boden, R; (2002) A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection. In: CANCER. (pp. 1249 - 1257). JOHN WILEY & SONS INC

Flynn, AA; Pedley, RB; Green, AJ; Boxer, GM; Boden, R; Bhatia, J; Morris, R; (2002) Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour. INT J RADIAT BIOL , 78 (5) 407 - 415. 10.1080/09553000110117818.

Ford, HER; Mitchell, F; Cunningham, D; Farrugia, DC; Hill, ME; Rees, C; Calvert, AH; (2002) Patterns of elevation of plasma 2 '-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. CLIN CANCER RES , 8 (1) 103 - 109.

Fordham-Skelton, AP; Chilley, P; Lumbreras, V; Reignoux, S; Fenton, TR; Dahm, CC; Pages, M; (2002) A novel higher plant protein tyrosine phosphatase interacts with SNF1-related protein kinases via a KIS (kinase interaction sequence) domain. Plant J , 29 (6) pp. 705-715.

Francis, RJ; Sharma, SK; Springer, C; Green, AJ; Hope-Stone, LD; Sena, L; Martin, J; (2002) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. BRIT J CANCER , 87 (6) 600 - 607. 10.1038/sj.bjc.6600517.


Gasco, M; Sullivan, A; Repellin, C; Brooks, L; Farrell, PJ; Tidy, JA; Dunne, B; (2002) Coincident inactivation of 14-3-3σ and p16INK4a is an early event in vulval squamous neoplasia. Oncogene , 21 (12) pp. 1876-1881. 10.1038/sj.onc.1205256.

Gore, M; Oza, A; Rustin, G; Malfetano, J; Calvert, H; Clarke-Pearson, D; Carmichael, J; (2002) A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. EUR J CANCER , 38 (1) 57 - 63.

Gower, NH; Rudd, RM; James, LE; Gregory, W; Eisen, T; Lee, SM; Harper, PG; (2002) Gemcitabine/carboplatin (GC) versus mitomycin/ifosfamide/cisplatin (MIP): A randomised comparison in patients with advanced non-small cell lung cancer (NSCLC). BRITISH JOURNAL OF CANCER , 86 S1-S1.

Grimaldi, KA; McGurk, CJ; McHugh, PJ; Hartley, JA; (2002) PCR-based methods for detecting DNA damage and its repair at the sub-gene and single nucleotide levels in cells. MOL BIOTECHNOL , 20 (2) 181 - 196.


Harris, RA; Yang, A; Stein, RC; Lucy, K; Brusten, L; Herath, A; Parekh, R; (2002) Cluster analysis of an extensive human breast cancer cell line protein expression map database. PROTEOMICS , 2 (2) pp. 212-223. 10.1002/1615-9861(200202)2:2<212::AID-PROT212>3.0.CO;2-H.

Hartley, JA; Spanswick, VJ; Pedley, RB; Hollingshead, MG; Alley, MC; Schultz, R; Gregson, SJ; (2002) In vitro antitumor activity and in vivo DNA interstrand crosslinking by the novel pyrrolobenzodiazepine dimer SJG-136 (NSC 694501). In: (pp. 2432-).

Hartley, JA; Spanswick, VJ; Pedley, RB; Hollingshead, MG; Alley, MC; Schultz, R; Gregson, SJ; (2002) In vitro activity and in vivo DNA interstrand crosslinking by the novel pyrrolobenzodiazepine dimer SJG-136 (NSC 694501). In: (Proceedings) Proceedings American Association for Cancer Research. (pp. 489-).

Hoskin, PJ; (2002) Conformal radiotherapy to the prostate: are bigger fields better? Clinical Oncology , 14 (4) pp. 296-297.

Howard, TT; Lingerfelt, BM; Purnell, BL; Scott, AE; Price, CA; Townes, HM; McNulty, L; (2002) Novel furano analogues of duocarmycin C1 and C2: Design, synthesis, and biological evaluation of seco-iso-cyclopropylfurano[2,3-e]indoline (seco-iso-CFI) and seco-cyclopropyltetrahydrofurano[2,3-f]quinoline (seco-CFQ) analogues. BIOORGAN MED CHEM , 10 (9) 2941 - 2952.

Hughes, A; Calvert, P; Azzabi, A; Plummer, R; Johnson, R; Rusthoven, J; Griffin, M; (2002) Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J CLIN ONCOL , 20 (16) 3533 - 3544. 10.1200/JCO.2002.10.073.


Janinis, J; McTiernan, A; Driver, D; Mitchell, C; Cassoni, AM; Pringle, J; Kilby, A; (2002) A pilot study of short-course intensive multiagent chemotherapy in metastatic and axial skeletal osteosarcoma. ANN ONCOL , 13 (12) 1935 - 1944. 10.1093/annonc/mdf338.

Jones, B; Aird, E; Colyer, H; Dobbs, J; Harris, R; Hoskin, P; McKenzie, A; (2002) United Kingdom Radiation Oncology 1 conference (UKRO 1): Accuracy and uncertainty in radiotherapy. BRITISH JOURNAL OF RADIOLOGY , 75 (892) pp. 297-306.


Kiakos, K; Howard, TT; Lee, M; Hartley, JA; McHugh, PJ; (2002) Saccharomyces cerevisiae RAD5 influences the excision repair of DNA minor groove adducts. J BIOL CHEM , 277 (46) 44576 - 44581. 10.1074/jbc.M208169200. Gold open access

Koch, SSC; Thoresen, LH; Tikhe, JG; Maegley, KA; Almassy, RJ; Li, JK; Yu, XH; (2002) Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure. J MED CHEM , 45 (23) 4961 - 4974. 10.1021/jm02059n.


Lee, YC; Boehm, MK; Chester, KA; Begent, RHJ; Perkins, SJ; (2002) Reversible dimer formation and stability of the anti-tumour single-chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FT-IR spectroscopy. J MOL BIOL , 320 (1) 107 - 127. 10.1016/S0022-2836(02)00403-5.


Mayer, A; Spencer, DIR; Tolner, B; Purdy, D; Begent, RHJ; Chester, K; (2002) A recombinant fusion protein with potentially reduced immunogenicity for ADEPT. BRIT J CANCER , 86 S117 - S117.


Nehls, O; Klump, B; Arkenau, HT; Hass, HG; Greschniok, A; Gregor, M; Porschen, R; (2002) Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer , 87 (7) pp. 702-704. 10.1038/sj.bjc.6600543.

Nicholson, PW; Harland, SJ; (2002) Survival prospects after screen-detection of prostate cancer. BJU INT , 90 (7) 686 - 693. 10.1046/j.1464-4096.2002.03005.x.

Niyikiza, C; Baker, SD; Seitz, DE; Walling, JM; Nelson, K; Rusthoven, JJ; Stabler, SP; (2002) Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy. MOL CANCER THER , 1 (7) 545 - 552.

Niyikiza, C; Hanauske, AR; Rusthoven, JJ; Calvert, AH; Allen, R; Paoletti, P; Bunn, PA; (2002) Pemetrexed safety and dosing strategy. SEMIN ONCOL , 29 (6) 24 - 29. 10.1053/sonc.2002.37465.


O'Hare, CC; Mack, D; Tandon, M; Sharma, SK; Lown, JW; Kopka, ML; Dickerson, RE; (2002) DNA sequence recognition in the minor groove by crosslinked polyamides: The effect of N-terminal head group and linker length on binding affinity and specificity. P NATL ACAD SCI USA , 99 (1) 72 - 77.

Okkenhaug, K; Bilancio, A; Farjot, G; Priddle, H; Sancho, S; Peskett, E; Pearce, W; (2002) Impaired B and T cell antigen receptor signaling in p110 delta PI 3-kinase mutant mice. SCIENCE , 297 (5583) pp. 1031-1034.


Panaretou, B; Siligardi, G; Meyer, P; Maloney, A; Sullivan, JK; Singh, S; Millson, SH; (2002) Activation of the ATPase activity of Hsp90 by the stress-regulated cochaperone Aha1. MOLECULAR CELL , 10 (6) pp. 1307-1318. 10.1016/S1097-2765(02)00785-2.

Parmar, MKB; Adams, M; Balestrino, M; Bertelsen, K; Bonazzi, C; Calvert, H; Colombo, N; (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. LANCET , 360 (9332) 505 - 515.

Patel, K; Stein, R; Benvenuti, S; Zvelebil, MJ; (2002) Combinatorial use of mRNA and two-dimensional electrophoresis expression data to choose relevant features for mass spectrometric identification. PROTEOMICS , 2 (10) pp. 1464-1473. 10.1002/1615-9861(200210)2:10<1464::AID-PROT1464>3.0.CO;2-9.

Paul, MJ; Summers, Y; Calvert, AH; Rustin, G; Brampton, MH; Thatcher, N; Middleton, MR; (2002) Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. MELANOMA RES , 12 (2) 175 - 178.

Pedley, RB; El-Emir, E; Flynn, AA; Boxer, GM; Dearling, J; Raleigh, JA; Hill, SA; (2002) Synergy between vascular targeting agents and antibody-directed therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS , 54 (5) 1524 - 1531.

Peters, GJ; Backus, HHJ; Freemantle, S; van Triest, B; Codacci-Pisanelli, G; van der Wilt, CL; Smid, K; (2002) Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE , 1587 (2-3) 194 - 205.

Petrie, IA; Flynn, AA; Pedley, RB; Green, AJ; El-Emir, E; Dearling, JLJ; Boxer, GM; (2002) Spatial accuracy of 3D reconstructed radioluminographs of serial tissue sections and resultant absorbed dose estimates. PHYS MED BIOL , 47 (20) 3651 - 3661.

Pinto, M; (2002) Induction and rejoining of DNA double-strand breaks in human cells after exposure to ionising radiation: an experimental and modelling approach. Doctoral thesis, University of London. Green open access

Plummer, R; Ghielmini, M; Calvert, P; Voi, M; Renard, J; Gallant, G; Gupta, E; (2002) Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. CLIN CANCER RES , 8 (9) 2788 - 2797.


Reddy, A; Yuille, M; Sullivan, A; Repellin, C; Bell, A; Tidy, JA; Evans, DJ; (2002) Analysis of CHK2 in vulval neoplasia. Br J Cancer , 86 (5) pp. 756-760. 10.1038/sj.bjc.6600131.


Salim, K; Fenton, T; Bacha, J; Urien-Rodriguez, H; Bonnert, T; Skynner, HA; Watts, E; (2002) Oligomerization of G-protein-coupled receptors shown by selective co-immunoprecipitation. J Biol Chem , 277 (18) pp. 15482-15485. 10.1074/jbc.M201539200.

Saunders, MI; (2002) Chart and chemotherapy. Clinical Oncology , 14 (4) pp. 331-332.

Saunders, MI; Rojas, A; Lyn, BE; Wilson, E; Phillips, H; (2002) Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer. Clin Oncol (R Coll Radiol) , 14 (5) pp. 352-360.

Schellens, JHM; Heinrich, B; Lehnert, M; Gore, ME; Kaye, SB; Dombernowsky, P; Paridaens, R; (2002) Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies. INVEST NEW DRUG , 20 (1) 83 - 93.

Sharma, SK; Pedley, RB; Bhatia, J; Irwin, HL; El-Emir, E; Boxer, GM; Boden, RW; (2002) Antibody-directed enzyme prodrug therapy (ADEPT): comparison in two colorectal carcinoma xenografts. In: (Proceedings) proceedings AmericanAssociation for Cancer Research. (pp. 943-).

Sierens, J; Hartley, JA; Campbell, MJ; Leathem, AJC; Woodside, JV; (2002) In vitro isoflavone supplementation reduces hydrogen peroxide-induced DNA damage in sperm. TERATOGEN CARCIN MUT , 22 (3) 227 - 234. 10.1002/tcm.10015.

Simpson, AB; Calvert, PM; Sludden, JA; Boddy, AV; Griffin, MJ; Schatzlein, A; Wilson, P; (2002) Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules. ANN ONCOL , 13 (3) 399 - 402. 10.1093/annonc/mdf041.

Spanswick, VJ; Craddock, C; Sekhar, M; Mahendra, P; Shankaranarayana, P; Hughes, RG; Hochhauser, D; (2002) Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. BLOOD , 100 (1) 224 - 229. Green open access

Spanswick, VJ; Craddock, C; Sekhar, M; Mahendra, P; Shankaranarayana, P; Hughes, RG; Hochhauser, D; (2002) Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood , 100 (1) pp. 224-229.

Spencer, DI; Robson, L; Purdy, D; Whitelegg, NR; Michael, NP; Bhatia, J; Sharma, SK; (2002) A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics. Proteomics , 2 (3) pp. 271-279.

Spencer, DIR; Robson, L; Purdy, D; Whitelegg, NR; Michael, NP; Bhatia, J; Sharma, SK; (2002) A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics. PROTEOMICS , 2 (3) 271 - 279.

Spender, LC; Cornish, GH; Sullivan, A; Farrell, PJ; (2002) Expression of transcription factor AML-2 (RUNX3, CBF(alpha)-3) is induced by Epstein-Barr virus EBNA-2 and correlates with the B-cell activation phenotype. J Virol , 76 (10) pp. 4919-4927.

Stein, RC; Zvelebil, MJ; (2002) The application of 2D gel-based proteomics methods to the study of breast cancer. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA , 7 (4) pp. 385-393. 10.1023/A:1024034031472.

Stephan, DA; Howell, GR; Teslovich, TM; Coffey, AJ; Smith, L; Bailey-Wilson, JE; Malechek, L; (2002) Physical and transcript map of the hereditary prostate cancer region at Xq27. GENOMICS , 79 (1) 41 - 50. 10.1006/geno.2001.6681.

Sullivan, A; Yuille, M; Repellin, C; Reddy, A; Reelfs, O; Bell, A; Dunne, B; (2002) Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene , 21 (9) pp. 1316-1324. 10.1038/sj.onc.1205207.


Tchilian, EZ; Dawes, R; Ramaley, PA; Whitworth, JA; Yuldasheva, N; Wells, RS; Watera, C; (2002) A CD45 polymorphism associated with abnormal splicing is absent in African populations. IMMUNOGENETICS , 53 (10-11) 980 - 983. 10.1007/s00251-001-0410-z.

Thomas, HD; Porter, DJ; Bartelink, I; Nobbs, JR; Cole, M; Elliott, S; Newell, DR; (2002) Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide. BRIT J CLIN PHARMACO , 53 (1) 83 - 91.

Toth, JL; Price, CA; Madsen, EC; Handl, HL; Hudson, SJ; Hubbard, RB; Bowen, JP; (2002) Sequence selective recognition of DNA by hairpin conjugates of a racemic seco-cyclopropaneindoline-2-benzofurancarboxamide and polyamides. Bioorg Med Chem Lett , 12 (16) pp. 2245-2248.


Vassileva, V; Millar, A; Briollais, L; Chapman, W; Bapat, B; (2002) Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. CANCER RESEARCH , 62 (14) pp. 4095-4099.


Whelan, JS; Burcombe, RJ; Janinis, J; Baldelli, AM; Cassoni, AM; (2002) A systematic review of the role of pulmonary irradiation in the management of primary bone tumours. Ann Oncol , 13 (1) pp. 23-30.

Winfield, E; Deighton, A; Venables, K; Hoskin, PJ; Aird, EGA; (2002) Survey of UK breast radiotherapy techniques: Background prior to the introduction of the quality assurance programme for the START (Standardisation of Radiotherapy) Trial in breast cancer. Clinical Oncology , 14 (4) pp. 267-271.

Wong, WL; Campbell, H; Saunders, M; (2002) Positron emission tomography (PET) - Evaluation of 'indeterminate pulmonary lesions'. Clinical Oncology , 14 (2) pp. 123-128.


Zehnder, D; Bland, R; Chana, RS; Wheeler, DC; Howie, AJ; Williams, MC; Stewart, PM; (2002) Synthesis of 1,25-dihydroxyvitamin D-3 by human endothelial cells is regulated by inflammatory cytokines: A novel autocrine determinant of vascular cell adhesion. J AM SOC NEPHROL , 13 (3) ? - ?.

Zhang, J; Vanhaesebroeck, B; Rittenhouse, SE; (2002) Human platelets contain p110 delta phosphoinositide 3-kinase. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS , 296 (1) pp. 178-181. 10.1016/S0006-291X(02)00744-1.

Zhang, J; Vanhaesebroeck, B; Rittenhouse, SE; (2002) Human platelets contain p110 delta phosphoinositide 3-kinase. BIOCHEM BIOPH RES CO , 296 (1) 178 - 181.

Zhyvoloup, A; Nemazanyy, I; Babich, A; Panasyuk, G; Pobigailo, N; Vudmaska, M; Naidenov, V; (2002) Molecular cloning of CoA synthase - The missing link in CoA biosynthesis. J BIOL CHEM , 277 (25) 22107 - 22110. 10.1074/jbc.C200195200. Gold open access

This list was generated on Sun Feb 26 03:11:35 2017 GMT.